Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Immunology
|
April 1, 1981
Quantitative differences between complement factor-B phenotypes
J P Mortensen, L U Lamm
Immunology
|
April 1, 1980
Studies on the C2-deficiency gene in man
J P Mortensen, L Buskjaer, L U Lamm
Human Genetics
|
January 1, 1981
Family studies of complement C4 and HLA in man
G Bruun-Petersen, L U Lamm, I J Sørensen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 3, 2006
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer
P Pfeiffer, J P Mortensen, B Bjerregaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
P Pfeiffer, H Sørbye, H Ehrsson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Immunology
|
April 1, 1981
Quantitative differences between complement factor-B phenotypes
J P Mortensen, L U Lamm
Immunology
|
April 1, 1980
Studies on the C2-deficiency gene in man
J P Mortensen, L Buskjaer, L U Lamm
Human Genetics
|
January 1, 1981
Family studies of complement C4 and HLA in man
G Bruun-Petersen, L U Lamm, I J Sørensen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 3, 2006
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer
P Pfeiffer, J P Mortensen, B Bjerregaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
P Pfeiffer, H Sørbye, H Ehrsson, et al.
Page
of 1